Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 2
1965 1
1967 3
1968 2
1969 2
1971 3
1972 5
1973 2
1974 1
1975 3
1976 4
1977 4
1978 5
1979 8
1980 4
1981 5
1982 5
1983 10
1984 9
1985 9
1986 15
1987 20
1988 13
1989 16
1990 32
1991 29
1992 32
1993 26
1994 34
1995 45
1996 34
1997 34
1998 46
1999 54
2000 53
2001 63
2002 62
2003 58
2004 81
2005 112
2006 115
2007 128
2008 122
2009 149
2010 174
2011 203
2012 220
2013 243
2014 274
2015 267
2016 282
2017 349
2018 339
2019 432
2020 575
2021 665
2022 682
2023 666
2024 168

Text availability

Article attribute

Article type

Publication date

Search Results

6,298 results

Results by year

Filters applied: . Clear all
Page 1
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
Zhou C, Solomon B, Loong HH, Park K, Pérol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak MP, Santini FC, Elamin YY, Drilon A, Wolf J, Payakachat N, Uh MK, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin AB, Lin BK, Goto K; LIBRETTO-431 Trial Investigators. Zhou C, et al. Among authors: lin bk. N Engl J Med. 2023 Nov 16;389(20):1839-1850. doi: 10.1056/NEJMoa2309457. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870973 Clinical Trial.
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.
Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, Führer D, Keam B, Bardet S, Sherman EJ, Tahara M, Hu MI, Singh R, Lin Y, Soldatenkova V, Wright J, Lin B, Maeda P, Capdevila J, Wirth LJ; LIBRETTO-531 Trial Investigators. Hadoux J, et al. Among authors: lin b. N Engl J Med. 2023 Nov 16;389(20):1851-1861. doi: 10.1056/NEJMoa2309719. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870969 Clinical Trial.
Reply.
Lin BR, Al-Khersan H, Rowsey T, West M, Lin A, Qu P, Bitrian E, Hudson J, Venincasa M, Fan J, Gutkind N, Diaz JD, Parekh P, Sultan H, Yannuzzi NA. Lin BR, et al. Ophthalmology. 2023 Oct;130(10):e35-e36. doi: 10.1016/j.ophtha.2023.07.003. Epub 2023 Jul 10. Ophthalmology. 2023. PMID: 37437782 No abstract available.
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.
Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC, Doria-Rose NA, O'Dell S, Schmidt SD, Corbett KS, Swanson PA 2nd, Padilla M, Neuzil KM, Bennett H, Leav B, Makowski M, Albert J, Cross K, Edara VV, Floyd K, Suthar MS, Martinez DR, Baric R, Buchanan W, Luke CJ, Phadke VK, Rostad CA, Ledgerwood JE, Graham BS, Beigel JH; mRNA-1273 Study Group. Anderson EJ, et al. Among authors: lin bc. N Engl J Med. 2020 Dec 17;383(25):2427-2438. doi: 10.1056/NEJMoa2028436. Epub 2020 Sep 29. N Engl J Med. 2020. PMID: 32991794 Free PMC article. Clinical Trial.
An improved reporter identifies ruxolitinib as a potent and cardioprotective CaMKII inhibitor.
Reyes Gaido OE, Pavlaki N, Granger JM, Mesubi OO, Liu B, Lin BL, Long A, Walker D, Mayourian J, Schole KL, Terrillion CE, Nkashama LJ, Hulsurkar MM, Dorn LE, Ferrero KM, Huganir RL, Müller FU, Wehrens XHT, Liu JO, Luczak ED, Bezzerides VJ, Anderson ME. Reyes Gaido OE, et al. Among authors: lin bl. Sci Transl Med. 2023 Jun 21;15(701):eabq7839. doi: 10.1126/scitranslmed.abq7839. Epub 2023 Jun 21. Sci Transl Med. 2023. PMID: 37343080
NRF2, a Superstar of Ferroptosis.
Yan R, Lin B, Jin W, Tang L, Hu S, Cai R. Yan R, et al. Among authors: lin b. Antioxidants (Basel). 2023 Sep 8;12(9):1739. doi: 10.3390/antiox12091739. Antioxidants (Basel). 2023. PMID: 37760042 Free PMC article. Review.
Engineered aptamers for molecular imaging.
Lin B, Xiao F, Jiang J, Zhao Z, Zhou X. Lin B, et al. Chem Sci. 2023 Nov 21;14(48):14039-14061. doi: 10.1039/d3sc03989g. eCollection 2023 Dec 13. Chem Sci. 2023. PMID: 38098720 Free PMC article. Review.
Anti-PD-1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2-Positive Gastric Cancer through Gasdermin B-Cleavage Induced Pyroptosis.
Lin W, Zhang Y, Yang Y, Lin B, Zhu M, Xu J, Chen Y, Wu W, Chen B, Chen X, Liu J, Wang H, Teng F, Yu X, Wang H, Lu J, Zhou Q, Teng L. Lin W, et al. Among authors: lin b. Adv Sci (Weinh). 2023 Oct;10(30):e2303908. doi: 10.1002/advs.202303908. Epub 2023 Aug 16. Adv Sci (Weinh). 2023. PMID: 37587833 Free PMC article.
6,298 results